Applied DNA Sciences (NASDAQ:APDN) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a report issued on Saturday. The firm set a “hold” rating on the technology company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Applied DNA Sciences from $2.00 to $1.50 and set a “buy” rating for the company in a research report on Friday, February 9th.

Applied DNA Sciences Stock Performance

Shares of APDN opened at $0.38 on Friday. The stock’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $0.71. Applied DNA Sciences has a 12 month low of $0.37 and a 12 month high of $1.86. The company has a market capitalization of $6.43 million, a PE ratio of -0.70 and a beta of 0.07.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings data on Thursday, February 8th. The technology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.22. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $0.70 million. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. Equities research analysts predict that Applied DNA Sciences will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Applied DNA Sciences

A number of large investors have recently bought and sold shares of the stock. AMH Equity Ltd boosted its position in shares of Applied DNA Sciences by 76.3% during the 3rd quarter. AMH Equity Ltd now owns 587,232 shares of the technology company’s stock worth $711,000 after purchasing an additional 254,232 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Applied DNA Sciences by 3.4% in the third quarter. Vanguard Group Inc. now owns 523,691 shares of the technology company’s stock worth $634,000 after acquiring an additional 17,241 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Applied DNA Sciences by 28.8% in the fourth quarter. Geode Capital Management LLC now owns 129,355 shares of the technology company’s stock worth $214,000 after acquiring an additional 28,897 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Applied DNA Sciences in the third quarter valued at approximately $146,000. Finally, BlackRock Inc. increased its stake in Applied DNA Sciences by 63.7% during the 3rd quarter. BlackRock Inc. now owns 101,661 shares of the technology company’s stock valued at $114,000 after purchasing an additional 39,541 shares in the last quarter. 22.22% of the stock is currently owned by institutional investors and hedge funds.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.